ESR1 and gastric cancer: Currently, estrogen-targeting hormone therapy for ER-positive CUP is not recommended unless breast cancer is expected as an origin[10,31]; however, exploring GC specific markers as well as investigating estrogen-targeting hormone therapy for GC potentially improves the prognosis of CUP that are actually originated from GC.